When dichotomizing patients based on above or below median presence of CD8+ cells and analyzing patient survival within these two groups, it was clear that patients with a higher degree of tumor-infiltrating CD8+ cells had a longer overall survival, defined as time after treatment until death of any cause (Figure 4a). This evidence concerns the gene CD8A and neoplasm.